// App-Quantinova.ai

6.1 1647 : Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: Results from the phase IIIb ANDHI trial

Researchers

Presenter

  • Canonica GW

Principal Investigators

  • Harrison TW

  • Chanez P

  • Menzella F

  • Louis R

  • Cosio BG

  • Lugogo NL

  • Mohan A

  • Burden A

  • Mcdermott L

  • Garcia Gil E

  • Zangrilli JG

Medical Centers

  • Humanitas University and Humanitas Research Hospital, Milano, Italy

  • Nottingham NIHR BRC, University of Nottingham

  • Nottingham City Hospital, Nottingham, United Kingdom

  • Aix Marseille University, Marseille, France

  • Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy

  • University and CHU of Liège, Liège, Belgium

  • Hospital Son Espases‐IdISBa and Ciberes, Palma De Mallorca, Spain

  • University of Michigan Medical School, Ann Arbor, MI

  • East Carolina University - Brody School of Medicine, Greenville, North Carolina, United States

  • AstraZeneca, Gaithersberg, MD, United States,

  • AstraZeneca, Barcelona, Spain.

Locations

  • Italy

  • United Kingdom

  • France

  • Belgium

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Asthma

  • Spastic paraplegia, intellectual disability, nystagmus, and obesity

Biomarkers

  • N/A

Drug/Treatment

  • Benralizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved